SCHEMBL2395484

SCHEMBL2395484

COC(=O)c1ccc(NC(=O)c2cc3c4c(c2)CCCC4(C)CCC3)s1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 7/20 0.41
NR3C1 P04150 4/20 0.41
L3MBTL1 Q9Y468 3/20 0.41
TDP1 Q9NUW8 1/20 0.41
ALDH1A1 P00352 4/20 0.36
KDM4E B2RXH2 3/20 0.36
HPGD P15428 3/20 0.36
MAPT P10636 2/20 0.36
LMNA P02545 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
RAB9A P51151 2/20 0.35
NPC1 O15118 1/20 0.35
HSD17B10 Q99714 2/20 0.35
TSHR P16473 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
TP53 P04637 1/20 0.35
HDAC1 Q13547 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2396267 0.91 RNASEH1 (0.38) ARNR3C1ALDH1A1MAPTSMN1; SMN2
SCHEMBL2396265 0.82 SMN1; SMN2 (0.44) L3MBTL1ALDH1A1KDM4EHPGDMAPT
SCHEMBL2396145 0.81 AR (0.42) ARNR3C1L3MBTL1TDP1ALDH1A1
SCHEMBL2394353 0.79 NPC1 (0.50) ALDH1A1KDM4EHPGDMAPTSMN1; SMN2
SCHEMBL2397298 0.76 MEN1 (0.46) L3MBTL1KDM4EMAPTSMN1; SMN2RAB9A
SCHEMBL2394731 0.75 KDM4E (0.48) ALDH1A1KDM4EHPGDMAPTLMNA
SCHEMBL2390930 0.75 SMN1; SMN2 (0.50) ALDH1A1KDM4EMAPTSMN1; SMN2RAB9A
SCHEMBL2394352 0.74 NPC1 (0.45) TDP1ALDH1A1KDM4EMAPTLMNA
SCHEMBL2394316 0.74 RARA (0.46) ALDH1A1MAPTLMNASMN1; SMN2RAB9A
SCHEMBL2393263 0.74 SMN1; SMN2 (0.43) ALDH1A1KDM4EHPGDMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2189443-B1 TRICYCLIC AMIDE COMPOUND RES FOUND ITSUU LAB (JP) 2013-10-23 EP disclosed
US-8232300-B2 Tricyclic amide compound RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2012-07-31 US disclosed
US-8232300-B2 Tricyclic amide compound RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2012-07-31 US disclosed
US-8232300-B2 Tricyclic amide compound RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2012-07-31 US disclosed
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2011-09-01 US disclosed
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2011-09-01 US disclosed
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2011-09-01 US disclosed
EP-2189443-A1 TRICYCLIC AMIDE COMPOUND Research Foundation Itsuu Laboratory (JP) 2010-05-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RXRA, RXRB, RXRG AR 74/4885NR3C1 191/4885L3MBTL1 4033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.